These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 8995588)

  • 1. Expression of CD59, a regulator of the membrane attack complex of complement, on human skeletal muscle fibers.
    Navenot JM; Villanova M; Lucas-Héron B; Malandrini A; Blanchard D; Louboutin JP
    Muscle Nerve; 1997 Jan; 20(1):92-6. PubMed ID: 8995588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation and functional assay of the membrane complement inhibitors CD55 (DAF) and CD59 (MIRL).
    Parker CJ
    Curr Protoc Immunol; 2001 May; Chapter 13():13.5.1-13.5.18. PubMed ID: 18432718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins.
    Koski CL; Estep AE; Sawant-Mane S; Shin ML; Highbarger L; Hansch GM
    J Neurochem; 1996 Jan; 66(1):303-12. PubMed ID: 8522968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
    Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
    Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9.
    Farkas I; Baranyi L; Ishikawa Y; Okada N; Bohata C; Budai D; Fukuda A; Imai M; Okada H
    J Physiol; 2002 Mar; 539(Pt 2):537-45. PubMed ID: 11882685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The terminal complement complex is generated in chronic leg ulcers in the absence of protectin (CD59).
    Balslev E; Thomsen HK; Danielsen L; Sheller J; Garred P
    APMIS; 1999 Nov; 107(11):997-1004. PubMed ID: 10598871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical protection from renal ischemia reperfusion injury by CD55 and CD59.
    Yamada K; Miwa T; Liu J; Nangaku M; Song WC
    J Immunol; 2004 Mar; 172(6):3869-75. PubMed ID: 15004194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trimeresurus flavoviridis (habu snake) venom induces human erythrocyte lysis through enzymatic lipolysis, complement activation and decreased membrane expression of CD55 and CD59.
    Yamamoto C; Tsuru D; Oda-Ueda N; Ohno M; Hattori S; Kim ST
    Pharmacol Toxicol; 2001 Oct; 89(4):188-94. PubMed ID: 11881969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.
    Miwa T; Zhou L; Hilliard B; Molina H; Song WC
    Blood; 2002 May; 99(10):3707-16. PubMed ID: 11986227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative Contribution of Cellular Complement Inhibitors CD59, CD46, and CD55 to Parainfluenza Virus 5 Inhibition of Complement-Mediated Neutralization.
    Li Y; Parks GD
    Viruses; 2018 Apr; 10(5):. PubMed ID: 29693588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies.
    Gelderman KA; Blok VT; Fleuren GJ; Gorter A
    Lab Invest; 2002 Apr; 82(4):483-93. PubMed ID: 11950905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Localization of the complement membrane attack complex inhibitor (CD59) in human conjunctiva and lacrimal gland.
    Bardenstein DS; Dietz Y; Lass JH; Medof ME
    Curr Eye Res; 1994 Dec; 13(12):851-5. PubMed ID: 7536649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for membrane attack complex inhibition by CD59.
    Couves EC; Gardner S; Voisin TB; Bickel JK; Stansfeld PJ; Tate EW; Bubeck D
    Nat Commun; 2023 Feb; 14(1):890. PubMed ID: 36797260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research.
    Thielen AJF; van Baarsen IM; Jongsma ML; Zeerleder S; Spaapen RM; Wouters D
    J Immunol Methods; 2018 May; 456():15-22. PubMed ID: 29447841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours.
    Schmitt CA; Schwaeble W; Wittig BM; Meyer zum Büschenfelde KH; Dippold WG
    Eur J Cancer; 1999 Jan; 35(1):117-24. PubMed ID: 10211099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific collaboration between rat membrane complement regulators Crry and CD59 protects peritoneum from damage by autologous complement activation.
    Mizuno T; Mizuno M; Morgan BP; Noda Y; Yamada K; Okada N; Yuzawa Y; Matsuo S; Ito Y
    Nephrol Dial Transplant; 2011 Jun; 26(6):1821-30. PubMed ID: 21098015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of the CD55 and CD59, membrane inhibitors of complement on HIV-1 particles as a function of complement-mediated virolysis.
    Nakamura M; Okada H; Sasaki H; Yoshida K; Kamada M; Okada N; Terada M; Ohno T
    Microbiol Immunol; 1996; 40(8):561-7. PubMed ID: 8887350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins.
    Sohn JH; Kaplan HJ; Suk HJ; Bora PS; Bora NS
    Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3492-502. PubMed ID: 11006244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues.
    Thorsteinsson L; O'Dowd GM; Harrington PM; Johnson PM
    APMIS; 1998 Sep; 106(9):869-78. PubMed ID: 9808413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Test for ability of decay-accelerating factor (DAF, CD55) and CD59 to alleviate complement-mediated damage of xeno-erythrocytes.
    Miyagawa S; Shirakura R; Matsumiya G; Nakata S; Matsuda H; Hatanaka M; Matsumoto M; Kitamura H; Seya T
    Scand J Immunol; 1993 Jul; 38(1):37-44. PubMed ID: 7687071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.